Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
· Abatacept [Orencia] - 17
· Adalimumab [Humira] - 16
· Adalimumab Biosimilars - 372
· Apremilast [Otezla] - NIL
· Baricitinib [Olumiant] - 19
· Bimekizumab [Bimzelx] - <5
· Certolizumab [Cimzia] - 45
· Etanercept [Enbrel] - 17
· Etanercept Biosimilars - 180
· Filgotinib [Jyseleca] - <5
· Golimumab [Simponi] - 17
· Guselkumab [Tremfya] - <5
· Infliximab [Remicade] - NIL
· Infliximab Biosimilars - NIL
· Ixekizumab [Taltz] - NIL
· Risankizumab [Skyrizi] - NIL
· Rituximab [MabThera] - NIL
· Rituximab Biosimilars - NIL
· Sarilumab [Kevzara] - 49
· Secukinumab [Cosentyx] - 12
· Tocilizumab [Ro Actemra] - 18
· Tocilizumab Biosimilars - NIL
· Tofacitinib [Xeljanz] - 12
· Upadacitinib [Rinvoq] - 14
· Ustekinumab [Stelara] - <5
Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:
· Abatacept [Orencia] - NIL
· Adalimumab [Humira] - 7
· Adalimumab Biosimilars - 45
· Apremilast [Otezla] - NIL
· Bimekizumab [Bimzelx] - <5
· Certolizumab [Cimzia] - 11
· Etanercept [Enbrel] - <5
· Etanercept Biosimilars - 34
· Golimumab [Simponi] - <5
· Guselkumab [Tremfya] - <5
· Infliximab [Remicade] - NIL
· Infliximab Biosimilars - NIL
· Ixekizumab [Taltz] - NIL
· Risankizumab [Skyrizi] - NIL
· Secukinumab [Cosentyx] - 5
· Tofacitinib [Xeljanz] - <5
· Upadacitinib [Rinvoq] - <5
· Ustekinumab [Stelara] - <5